Novel bone-targeting agents in prostate cancer

被引：2

作者：

Albany, C. ^{[1
]}

Hahn, N. M. ^{[1
]}

机构：

[1] Indiana Univ, Melvin & Bren Simon Canc Ctr, Dept Med, Indianapolis, IN 46202 USA

来源：

PROSTATE CANCER AND PROSTATIC DISEASES | 2014年 / 17卷 / 02期

关键词：

ANDROGEN-DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; ZOLEDRONIC ACID; PHASE-II; OSTEOCLAST DIFFERENTIATION; INCREASED SURVIVAL; MEN; RECEPTOR; METASTASIS;

D O I：

10.1038/pcan.2014.12

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Prostate cancer (PC) is the most commonly diagnosed non-skin cancer and the second leading cause of cancer death among American men. Bone is by far the most common site for metastasis. The median survival of patients from the development of bone metastases is similar to 3 years. During this period, patients are at increased-risk of skeletal-related events (SREs) including: intractable bone pain, pathological fractures and spinal-cord compression. Several novel bone-targeted agents including bisphosphonates, receptor activator of nuclear factor kappa B (RANK) ligand monoclonal antibodies, endothelin receptor antagonists, bone-seeking radioisotopes, selective estrogen receptor (ER) modulators and tyrosine kinase inhibitors are now available and under evaluation in clinical trials in PC patients with bone metastases. This review article will provide an overview of the multiple emerging novel bone-targeted therapies in PC.

引用

页码：112 / 118

页数：7

共 52 条

[1]

Araujo John C, 2013, J CLIN ONCOL S6, V31

[2]

Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy [J].

Basaria, S ;

Muller, DC ;

Carducci, MA ;

Egan, J ;

Dobs, AS .

CANCER, 2006, 106 (03) :581-588

[3]

Osteoclast differentiation and activation [J].

Boyle, WJ ;

Simonet, WS ;

Lacey, DL .

NATURE, 2003, 423 (6937) :337-342

[4]

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial [J].

Carducci, MA ;

Padley, RJ ;

Breul, J ;

Vogelzang, NJ ;

Zonnenberg, BA ;

Daliani, DD ;

Schulman, CC ;

Nabulsi, AA ;

Humerickhouse, RA ;

Weinberg, MA ;

Schmitt, JL ;

Nelson, JB .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :679-689

[5]

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer [J].

Carducci, Michael A. ;

Saad, Fred ;

Abrahamsson, Per-Anders ;

Dearnaley, David R. ;

Schulman, Claude C. ;

North, Scott A. ;

Sleep, Darryl J. ;

Isaacson, Jeffrey D. ;

Nelson, Joel B. .

CANCER, 2007, 110 (09) :1959-1966

[6]

Targeting bone metastasis in prostate cancer with endothelin receptor antagonists [J].

Carducci, Michael A. ;

Jimeno, Antonio .

CLINICAL CANCER RESEARCH, 2006, 12 (20) :6296S-6300S

[7]

Cheetham PJ, 2012, ONCOLOGY-NY, V26, P330

[8]

Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616

[9]

Advances in the use of bisphosphonates in the prostate cancer setting [J].

Coxon, JP ;

Oades, GM ;

Colston, KW ;

Kirby, RS .

PROSTATE CANCER AND PROSTATIC DISEASES, 2004, 7 (02) :99-104

[10]

Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

← 1 2 3 4 5 6 →